



Stephan Christgau, PhD

Senior Partner
Novo Seeds

Stephan Christgau joined Novo Holdings in 2007. Prior to joining Novo Seeds, Stephan was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment.

Previously Stephan has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S.

Stephan currently serves on the Board of Directors of Acesion Pharma, Afyx, Forendo Pharma, Galecto Biotech, Heparagenix, IO Biotech and Macrophage Pharma.

Stephan also serves as chairman for VentureCup, a non-profit university entrepreneurship organization.

